Key result
Elevated sIL-2R levels normalize over 2 months after successful PTCA in stable angina.
Why the study?
The role of T lymphocyte activation in stable angina pectoris patients undergoing PTCA and the influence of PTCA on this activation were not well characterized.
Does percutaneous transluminal coronary angioplasty reduce T lymphocyte activation (sIL-2R levels) in patients with stable angina pectoris?
Comparison
Stable angina patients before and after PTCA vs healthy control subjects
Design
Observational cohort study
Follow-up
2 months
Authors
Loading...
T-cell activation marker may decline after PTCA in select stable angina patients; leaves open its role as a follow-up biomarker.
Observational (n=39)
Does percutaneous transluminal coronary angioplasty reduce T lymphocyte activation (sIL-2R levels) in patients with stable angina pectoris?
T lymphocytes are activated in a subset of patients with stable angina, and elevated sIL-2R levels decrease toward normal following successful PTCA.
Blum et al. (1995) conducted an observational in Stable angina pectoris (n=39). Percutaneous transluminal coronary angioplasty (PTCA) vs. Healthy controls and pre-PTCA baseline was evaluated on Soluble interleukin-2 receptor (sIL-2R) levels. Among 24 men with stable angina undergoing PTCA, 11 had high pre-procedural soluble interleukin-2 receptor levels that decreased toward normal during the 2-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: